BEAM * logo

Beam Therapeutics BMV:BEAM * Stock Report

Last Price

Mex$531.00

Market Cap

Mex$46.3b

7D

0%

1Y

n/a

Updated

23 Dec, 2024

Data

Company Financials +

Beam Therapeutics Inc.

BMV:BEAM * Stock Report

Market Cap: Mex$46.3b

BEAM * Stock Overview

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More details

BEAM * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Beam Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Beam Therapeutics
Historical stock prices
Current Share PriceUS$531.00
52 Week HighUS$590.00
52 Week LowUS$440.00
Beta1.9
1 Month Change3.11%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-34.12%

Recent News & Updates

Recent updates

Shareholder Returns

BEAM *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how BEAM * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how BEAM * performed against the MX Market.

Price Volatility

Is BEAM *'s price volatile compared to industry and market?
BEAM * volatility
BEAM * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: BEAM *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine BEAM *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017472John Evansbeamtx.com

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. Fundamentals Summary

How do Beam Therapeutics's earnings and revenue compare to its market cap?
BEAM * fundamental statistics
Market capMex$46.35b
Earnings (TTM)-Mex$2.88b
Revenue (TTM)Mex$7.02b

6.6x

P/S Ratio

-16.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BEAM * income statement (TTM)
RevenueUS$349.64m
Cost of RevenueUS$406.19m
Gross Profit-US$56.55m
Other ExpensesUS$87.04m
Earnings-US$143.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.80
Gross Margin-16.17%
Net Profit Margin-41.07%
Debt/Equity Ratio0%

How did BEAM * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:04
End of Day Share Price 2024/11/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beam Therapeutics Inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Evan SeigermanBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research